What is Adynxx Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Adynxx's interest expense for the
three
months ended in Sep. 2019 was $ -0.22 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.60 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Adynxx's Operating Income for the
three
months ended in Sep. 2019 was $ -1.67 Mil. Adynxx's Interest Expense for the
three
months ended in Sep. 2019 was $ -0.22 Mil.
Adynxx did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Adynxx Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adynxx (OTCPK:ADYX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Adynxx's Interest Expense for the
three
months ended in Sep. 2019 was $-0.22 Mil. Its
Operating Income
for the
three
months ended in Sep. 2019 was $-1.67 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2019 was $0.52 Mil.
Adynxx's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as
| Adynxx did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Adynxx (Adynxx) Business Description
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
| Gregory J. Flesher |
director |
19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
| Brian H Dovey |
10 percent owner |
ONE PALMER SQUARE, PRINCETON NJ 08542 |
| Donald C. Manning |
officer: CHIEF MEDICAL OFFICER |
C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
| Pierre Legault |
director |
P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312 |
| Domain Partners Viii, L.p. |
10 percent owner |
C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
| Dp Viii Associates, L.p. |
10 percent owner |
C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
| Eckard Weber |
director |
C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542 |
| Brian K Halak |
10 percent owner |
C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542 |
| Nicole Vitullo |
10 percent owner |
3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
| James C Blair |
10 percent owner |
5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
| Jesse I Treu |
10 percent owner |
|
| Dennis Podlesak |
director |
C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
| Tpg Group Holdings (sbs) Advisors, Inc. |
10 percent owner |
C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
| James G Coulter |
10 percent owner |
301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
| David Bonderman |
10 percent owner |
301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
Adynxx (Adynxx) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADYX has been successfully added to your 